Mutations in genes encoding the RAS-RAF-MEK-ERK pathway protein can be detected in ovarian cancer, and BRAF and MEK inhibitor combinations are more effective and safer for ovarian cancer, especially for low-grade serosal ovarian cancer (12). This evidence concerns the gene BRAF and ovarian cancer.